C91.A2 Mature B-cell leukemia Burkitt-type, in relapse

Name of the Condition

• Mature B-cell leukemia Burkitt-type, in relapse
• ICD-10 Code: C91.A2

Summary

Mature B-cell leukemia Burkitt-type, in relapse, is an aggressive hematologic malignancy characterized by the recurrence of disease after a period of remission. It involves the uncontrolled proliferation of mature B cells, often with rapid progression and specific genetic abnormalities, such as MYC gene translocations. This condition is part of the Burkitt lymphoma/leukemia spectrum and requires prompt intervention due to its high growth rate.

Causes

The underlying cause of mature B-cell leukemia Burkitt-type involves genetic mutations, such as MYC gene translocations, that drive uncontrolled B-cell proliferation. Relapse may occur due to residual disease, treatment resistance, or biological factors affecting response, even after initial remission is achieved.

Risk Factors

• Immunodeficiency (e.g., HIV/AIDS)
• Epstein-Barr virus infection
• Certain genetic predispositions
• Geographic or demographic associations (e.g., higher incidence in some regions)
• Prior treatment resistance or inadequate therapy
• Short remission duration

Symptoms

• Recurrent or worsening fatigue and weakness
• Persistent or recurrent fever
• Unexplained weight loss
• Abdominal pain or swelling (due to organ involvement)
• Enlarged lymph nodes
• Neurological symptoms (if central nervous system is affected)
• Rapid onset of symptoms

Diagnosis

Diagnosis involves a physical examination, blood tests to assess cell counts and identify abnormal B cells, and imaging studies to evaluate organ involvement. Bone marrow biopsies confirm relapse by detecting malignant cells, and molecular testing may identify genetic abnormalities. Clinical history of prior remission is critical for context.

Treatment Options

Treatment typically includes intensive chemotherapy regimens, often with agents targeting rapid cell proliferation. Stem cell transplantation may be considered for eligible patients. Supportive care, such as managing infections or cytopenias, is essential. Treatment plans are tailored to disease status and patient factors.

Prognosis and Follow-Up

Prognosis depends on factors like response to therapy, disease burden, and patient health. Relapse indicates a more aggressive course, but outcomes vary. Regular follow-up with blood tests, imaging, and bone marrow evaluations is necessary to monitor for further recurrence or complications.

Complications

• Severe infections due to immunosuppression
• Organ dysfunction from rapid cell proliferation
• Neurological impairment (if central nervous system is involved)
• Treatment-related toxicities
• Disease progression or refractoriness

Lifestyle & Prevention

No specific lifestyle changes prevent relapse, but maintaining overall health supports recovery. Avoiding infections, adhering to treatment plans, and attending follow-up appointments are important. Immunizations and infection precautions may be recommended.

When to Seek Professional Help

Seek immediate medical attention for symptoms like persistent fever, unexplained weight loss, severe fatigue, or neurological changes. Prompt evaluation is critical to address relapse and adjust treatment.

Tips for Medical Coders

Document the diagnosis of relapse clearly, including clinical evidence (e.g., lab results, imaging) and prior remission status. Ensure the code C91.A2 is used only when relapse is confirmed, distinguishing it from active disease or remission. Include details on treatment response and any contributing factors to support accurate coding.